India Pharma Outlook Team | Monday, 20 July 2026
India has taken a major step in fighting Dengue Vaccine after the country's first vaccine received approval. The approval marks a key moment for public health.
It also offers a new option to reduce the burden of dengue infections. The Dengue Vaccine has been cleared by the Drugs Controller General of India (DCGI). It can be used for people between 4 and 60 years of age.
Takeda Biopharmaceuticals India announced that the DCGI has approved QDENGA for use in India. The vaccine becomes the first approved dengue vaccine in the country. It is designed to protect against all four dengue virus types. The approval comes as India continues to report seasonal dengue outbreaks across many states.
The approval allows QDENGA to be used in people aged 4 to 60 years. The vaccine is given in two doses. The second dose should be taken three months after the first.
One of the biggest advantages of the vaccine is that it does not require a blood test before vaccination. People do not need to confirm a previous dengue infection before receiving the vaccine.
Key highlights include:
Dengue remains one of India's biggest mosquito-borne health concerns. Every year, thousands of people are hospitalized due to the disease. Seasonal outbreaks also place pressure on hospitals and healthcare systems.
The approval of Takeda Biopharmaceuticals India brings another tool to fight dengue. Health experts believe vaccination can help lower the risk of severe disease. However, they also stress that mosquito control remains essential.
People should continue using mosquito repellents. They should also remove stagnant water around homes. Early medical care is still important if dengue symptoms appear.
Also Read: Driving Vaccine Adoption Beyond Pediatric Immunization in India
Before entering India, QDENGA had already received approvals in more than 40 countries. These include the European Union, the United Kingdom, Brazil, Indonesia, and Thailand.
The vaccine has been developed to protect against all four dengue virus serotypes. This is important because any of the four types can cause infection. Protection against multiple serotypes may help reduce the overall disease burden.
The approval is expected to strengthen India's efforts against dengue. It also adds another layer of protection alongside surveillance, mosquito control, and timely treatment.
While the approval is a major milestone, vaccination alone cannot eliminate dengue. Public health measures and community awareness will continue to play a vital role in preventing infections.
